Ethics and sample size

American Journal of Epidemiology

Volumn 161, Issue 2, 2005, Pages 105-110

  Bacchetti, Peter ^a,b   Wolf, Leslie E ^a   Segal, Mark R ^a   McCulloch, Charles E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ethics committees; Ethics, research; Sample size

Indexed keywords

EPIDEMIOLOGY; ETHICS; METHODOLOGY; SAMPLING BIAS;

ETHICAL ACCEPTABILITY; ETHICS; HUMAN; POPULATION RESEARCH; PROFESSIONAL STANDARD; REVIEW; RISK BENEFIT ANALYSIS; SAMPLE SIZE; STATISTICAL ANALYSIS;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

BIAS (EPIDEMIOLOGY); ETHICS, RESEARCH; HUMANS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 11844300444     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwi014     Document Type: Review

References (21)

1. Newell DJ. Type II errors and ethics. (Letter). BMJ 1978;4: 1789.
2. Altman DG. Statistics and ethics in medical research III: how large a sample? BMJ 1980;281:1336-8.
3. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000;283:2701-11.
4. Halpern SD, Karlawish JHT, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA 2002;288: 358-62.
5. Knapp TR. The overemphasis on power analysis. Nurs Res 1996;45:379-81.
6. Edwards SJL, Lilford RJ, Braunholtz D, et al. Why " underpowered" trials are not necessarily unethical. Lancet 1997;350:804-7.
7. Lilford R, Stevens AJ. Underpowered studies. Br J Surg 2002; 89:129-31.
8. Vail A. Experiences of a biostatistician on a U.K. research ethics committee. Stat Med 1998;17:2811-14.
9. Balasubramanian S. Underpowered studies. Br J Surg 2002;89: 811-12.
10. Department of Health and Human Services. Protection of human subjects (codified at 45 CFR §46.111(a)(2)). Washington, DC: Government Printing Office, 2002.
11. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: ethical principles and guidelines for the protection of human subjects of research. Washington, DC: Department of Health, Education, and Welfare, 1979. (DHEW publication no. (OS) 78-0012).
12. Rothman KJ. A show of confidence. N Engl J Med 1978;299: 1362-3.
13. Gardner MJ, Altman DG. Confidence intervals rather than p-values: estimation rather than hypothesis testing. BMJ 1986; 292:746-50.
14. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 1994;121:200-6.
15. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-94.
16. Hughes JR. The ethics of underpowered clinical trials. (Letter). JAMA 2002;288:2118.
17. Janosky JE. The ethics of underpowered clinical trials. (Letter). JAMA 2002;288:2118.
18. Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol 1995;48:23-40.
19. Horrobin DF. Are large clinical trials in rapidly lethal diseases usually unethical? Lancet 2003;361:685-7.
20. Hulley SB, Cummings SR, Browner WS, et al. Designing clinical research: an epidemiological approach. 2nd ed. Philadelphia, PA: Lippincott, Williams, and Wilkins, 2001:85.
21. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for non-uniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986;42:507-16.